nach oben

Drugs

Erschienen in:

01.02.2003 | Leading Article

Vaccines Against Drugs of Abuse

A Viable Treatment Option?

Erschienen in: Drugs | Ausgabe 4/2003

Einloggen, um Zugang zu erhalten

Abstract

Drug addiction is a chronically relapsing brain disorder. There is an urgent need for new treatment options for this disease because the relapse rate among drug abusers seeking treatment is quite high. During the past decade, many groups have explored the feasibility of using vaccines directed against drugs of abuse as a means of eliminating illicit drug use as well as drug overdose and neurotoxicity.

Vaccines work by inducing drug-specific antibodies in the bloodstream that bind to the drug of abuse and prevent its entry into the brain. The majority of work in this area has been conducted with vaccines and antibodies directed against cocaine and nicotine. On the basis of preclinical work, vaccines for cocaine and nicotine are now in clinical trials because they can offer long-term protection with minimal treatment compliance. In addition, vaccines and antibodies for phencyclidine, methamphetamine and heroin abuse are currently under development. An underlying theme in this research is the need for high concentrations of circulating drug-specific antibodies to reduce drug-seeking and drug-taking behaviour when the drug is repeatedly available, especially in high doses.

Although vaccines against drugs of abuse may become a viable treatment option, there are several drawbacks that need to be considered. These include: (i) a lack of protection against a structurally dissimilar drug that produces the same effects as the drug of choice; (ii) a lack of an effect on drug craving that predisposes an addict to relapse; and (iii) tremendous individual variability in antibody formation. Forced or coerced vaccination is not likely to work from a scientific perspective, and also carries serious legal and ethical concerns.

All things considered, vaccination against a drug of abuse is likely to work best with individuals who are highly motivated to quit using drugs altogether and as part of a comprehensive treatment programme. As such, the medical treatment of drug abuse will not be radically different from treatment of other chronic diseases.

Use of tradename is for identification purposes only and does not imply endorsement.

Bonese KF, Wainer BH, Fitch FW, et al. Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 1974; 252: 708–10PubMedCrossRef

Carroll FI, Howell LL, Kuhar MJ. Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J Med Chem 1999; 42: 2721–36PubMedCrossRef

Akbarzadeh A, Mehraby M, Zarbakhsh M, et al. Design and synthesis of a morphine-6-succinyl-bovine serum albumin hapten for vaccine development. Biotechnol Appl Biochem 1999; 30: 139–45PubMed

Morell V. Enzyme may blunt cocaine’s action. Science 1993; 259: 1828PubMedCrossRef

Landry DW, Zhao K, Yang GX, et al. Antibody-catalyzed degradation of cocaine. Science 1993; 259: 1899–901PubMedCrossRef

Yang G, Chun J, Arakawa-Uramoto H, et al. Anti-cocaine catalytic antibodies: a synthetic approach to improved antibody diversity. J Am Chem Soc 1996; 118: 5881–90CrossRef

Mets B, Winger G, Cabrera C, et al. A catalytic antibody against cocaine prevents cocaine’s reinforcing and toxic effects in rats. Proc Natl Acad Sci U S A 1998; 95: 10176–81PubMedCrossRef

Baird TJ, Deng SX, Landry DW, et al. Natural and artificial enzymes against cocaine. I: Monoclonal antibody 15A10 and the reinforcing effects of cocaine in rats. J Pharmacol Exp Ther 2000; 295: 1127–34

Basmadjian GP, Singh S, Sastrodjojo B, et al. Generation of polyclonal catalytic antibodies against cocaine using transition state analogs of cocaine conjugated to diptheria toxoid. Chem Pharm Bull (Tokyo) 1995; 43: 1902–11CrossRef

10.

Cashman JR, Berkman CE, Underiner GE. Catalytic antibodies that hydrolyze (−): cocaine obtained by a high-throughput procedure. J Pharmacol Exp Ther 2000 293: 952–61PubMed

11.

Bagasra O, Forman LJ, Howeedy A, et al. A potential vaccine for cocaine abuse prophylaxis. Immmunopharmacology 1992; 23: 173–9CrossRef

12.

Carrera MRA, Ashley JA, Parsons LH, et al. Suppression of psychoactive effects of cocaine by active immunization. Nature 1995; 378: 727–30PubMedCrossRef

13.

Carrera MRA, Ashley JA, Zhou B, et al. Cocaine vaccines: antibody protection against relapse in a rat model. Proc Natl Acad Sci U S A 2000; 97: 6202–6PubMedCrossRef

14.

Carrera MR, Ashley JA, Wirsching P, et al. A second-generation vaccine protects against the psychoactive effects of cocaine. Proc Natl Acad Sci U S A 2001; 98: 1988–92PubMedCrossRef

15.

Ettinger RH, Ettinger WF, Harless WE. Active immunization with cocaine-protein conjugate attenuates cocaine effects. Pharmacol Biochem Behav 1997; 58: 215–20PubMedCrossRef

16.

Johnson MW, Ettinger RH. Active cocaine immunization attenuates the discriminative properties of cocaine. Exp Clin Psychopharmacol 2000; 8: 163–7PubMedCrossRef

17.

Fox BS, Kantak KM, Edwards MA, et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 1996; 2: 1129–32PubMedCrossRef

18.

Evans SM, Cone EJ, Henning field JE. Arterial and venous cocaine plasma concentrations in humans: relationship to route of administration, cardiovascular effects and subjective effects. J Pharmacol Exp Ther 1996; 279: 1345–56PubMed

19.

Kantak KM, Collins SL, Lipman EG, et al. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology 2000; 148: 251–62PubMedCrossRef

20.

Kantak KM, Collins SL, Bond J, et al. Time course of changes in cocaine self-administration behavior during immunization with the cocaine vaccine IPC-1010. Psychopharmacology 2001; 153: 334–40PubMedCrossRef

21.

Kosten TR, Rosen M, Bond J, et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002; 20: 1196–204PubMedCrossRef

22.

TA-CD. Available from URL: http://www.xenova.co.uk/dc_ta_cd.html [Accessed 2002 Jan 15]

23.

Anti-cocaine addiction vaccine released from clinical hold phase Ha study results announced [online]. Available from URL: http://www.xenova.co.uk/PressReleases/pr_20010709_01.html [Accessed 2002 Jan 15]

24.

Schabacker DS, Kirschbaum KS, Segre M. Exploring the feasibility of anti-idiotypic cocaine vaccine: analysis of the specificity of anticocaine antibodies (Ab1) capable of inducing Ab2beta anti-idiotypic antibodies. Immunology 2000; 100: 48–56PubMedCrossRef

25.

Washton AM, Stone-Washton N. Abstinence and relapse in outpatient cocaine addicts. J Psychoactive Drugs 1990; 22: 135–47PubMedCrossRef

26.

Song N, Parker RB, Laizure SC. Cocaethylene formation in rat, dog and human hepatic microsomes. Life Sci 1999; 64: 2101–8PubMedCrossRef

27.

McCance-Katz EF, Kosten TR, Jatlow P. Concurrent use of cocaine and alcohol is more potent and potentially more toxic than use of either alone: a multiple-dose study. Biol Psychiatry 1998; 44: 250–9PubMedCrossRef

28.

Raven MA, Necessary BD, Danluck D, et al. Comparison of the reinforcing and anxiolytic effects of intravenous cocaine and cocaethylene. Exp Clin Psychopharmacol 2000; 8: 117–24PubMedCrossRef

29.

McKay JR, Alterman AI, Rutherford MJ, et al. The relationship of alcohol use to cocaine relapse in cocaine dependent patients in an aftercare study. J Stud Alcohol 1999; 60: 176–80PubMed

30.

Bordnick PS, Schmitz JM. Cocaine craving: an evaluation across treatment phases. J Subst Abuse 1998; 10: 9–17PubMedCrossRef

31.

Kuhar MJ, Carroll FI, Bharat N, et al. Anticocaine catalytic antibodies have no affinity for RTI compounds: implications for treatment. Synapse 2001; 41: 176–8PubMedCrossRef

32.

Hieda Y, Keyler DE, Vandevoort JT, et al. Active immunization alters the plasma nicotine concentration in rats. J Pharmacol Exp Ther 1997; 283: 1076–81PubMed

33.

Benowitz NL, Hall SM, Herning RI, et al. Smokers of low yield cigarettes do not consume less nicotine. N Engl J Med 1983; 309: 139–42PubMedCrossRef

34.

Henningfield JE, Stapleton JM, Benowitz NL, et al. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend 1993; 33: 23–9PubMedCrossRef

35.

Hieda Y, Keyler DE, Vandevoort JT, et al. Immunization of rats reduces nicotine distribution to brain. Psychopharmacology 1999; 143: 150–7PubMedCrossRef

36.

Keyler DE, Hieda Y, Peter J, et al. Altered disposition of repeated nicotine doses in rats immunized against nicotine. Nicotine Tob Res 1999; 1: 241–9PubMedCrossRef

37.

Hieda Y, Keyler DE, Ennifar S, et al. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol 2000; 22: 809–19PubMedCrossRef

38.

Pentel PR, Malin DH, Ennifar S, et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 2000; 65: 191–8PubMedCrossRef

39.

Malin DH, Lake JR, Lin A, et al. Passive immunization against nicotine prevents alleviation of nicotine abstinence syndrome. Pharmacol Biochem Behav 2001; 68: 87–92PubMedCrossRef

40.

Tuncok Y, Hieda Y, Keyler DE, et al. Inhibition of nicotine-induced seizures in rats by combining vaccination against nicotine with chronic nicotine infusion. Exp Clin Psychopharmacol 2001; 9: 228–34PubMedCrossRef

41.

Nabi Biopharmaceuticals reports encouraging preliminary results of NicVAX™ clinical trial [online]. Available from URL: http://www.nabi.com/releases/100302.html [Accessed 2002 Dec 30]

42.

Successful results of phase I trial for TA-NIC: first evaluation of anti-nicotine vaccine in man. Available from URL: http://www.xenova.co.uk/pressreleases/pr_20020614_01.html [Accessed 2002 Dec 30]

43.

Kasaian M. Development of a vaccine for treatment of nicotine dependence [abstract]. NIDA Symposium on Peripheral Blockers as Treatments for Substance Abuse and Dependence. 1998 Apr 27–28. Available from URL: http://165.112.78.61/meetsum/peripheral/index.html (Accessed 2002 Jan 15)

44.

de Villiers S, Lindblom N, Kalayanov G, et al. Active immunisation against nicotine can suppress the nicotine-induced stimulation of brain dopaminergic reward pathways [abstract 192.12]. Soc Neurosci 2000; 26 (Pt 1): 529

45.

Isomura S, Wirsching P, Jandra KD. An immunotherapeutic program for the treatment of nicotine addiction: hapten design and synthesis. J Org Chem 2001; 66: 4115–21PubMedCrossRef

46.

West R, Hajek P, Nilsson F, et al. Individual differences in preferences for and responses to four nicotine replacement products. Psychopharmacol 2001; 153: 225–30CrossRef

47.

Gross J, Stitzer ML. Nicotine replacement: ten-week effects on tobacco withdrawal symptoms. Psychopharmacol 1989; 98: 334–41CrossRef

48.

Owens SM, Mayersohn M. Phencyclidine-specific fab fragments alter phencyclidine disposition in dogs. Drug Metab Dispos 1986; 14: 52–8PubMed

49.

McClurkan MB, Valentine JL, Arnold L, et al. Disposition of a monoclonal anti-phencyclidine fab fragment of immunoglob-ulin G in rats. J Pharmacol Exp Ther 1993; 266: 1439–45PubMed

50.

Valentine JL, Arnold LW, Owens SM. Anti-phencyclidine monoclonal fab fragments markedly alter phencyclidine phar-macokinetics in rats. J Pharmacol Exp Ther 1994;269: 1079–85PubMed

51.

Valentine JL, Mayersohn M, Wessinger WD, et al. Anti-phencyclidine monoclonal fab fragments reverse phencyclid-ine-induced behavioral effects and ataxia in rats. J Pharmacol Exp Ther 1996; 278: 709–16PubMed

52.

Valentine JL, Owens SM. Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats. J Pharmacol Exp Ther 1996; 278: 717–24PubMed

53.

Proksch JW, Gentry WB, Owens SM. Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. J Pharmacol Exp Ther 2000; 292: 831–7PubMed

54.

Nature and effects of ketamine [online]. Available at URL: http://165.112.78.61/ResearchReports/hallucinogens/halluc4.html [Accessed 2002 Jan 15]

55.

Baldridge EB, Bessen HA. Phencyclidine. Emerg Med Clin North Am 1990; 8: 541–50PubMed

56.

Curran HV, Monaghan L. In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction 2001; 96: 749–60PubMedCrossRef

57.

Hardin JS, Wessinger WD, Proksch JW, et al. Pharmacodynamics of a monoclonal antiphencyclidine fab with broad selectivity for phencyclidine-like drugs. J Pharmacol Exp Ther 1998; 285: 1113–33PubMed

58.

Murray JB. Psychophysiological aspects of amphetamine-methamphetamine abuse. J Psychol 1998; 132: 227–37PubMedCrossRef

59.

Byrnes-Blake KA, Carroll FI, Abraham P, et al. Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats. Int J Immunopharmacol 2001; 1: 329–38CrossRef

60.

Cohen PJ. Immunization for prevention and treatment of cocaine abuse: legal and ethical implications. Drug Alcohol Depend 1997; 48: 167–74PubMedCrossRef

Titel: Vaccines Against Drugs of Abuse
A Viable Treatment Option?
Publikationsdatum: 01.02.2003
Erschienen in: Drugs / Ausgabe 4/2003
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200363040-00001

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2003

Management of Insomnia in Patients With Chronic Obstructive Pulmonary Disease

Antimicrobial Peptides

Losartan

Interactions Between Cyclosporin and Lipid-Lowering Drugs

Losartan

Losartan